Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant MUC16 (Sofituzumab Biosimilar) antibody

The Mammalian Cells Monoclonal anti-MUC16 (Sofituzumab Biosimilar) antibody (ABIN7488033) specifically detects MUC16 (Sofituzumab Biosimilar) in ELISA. The antibody is reactive with Human samples.
Catalog No. ABIN7488033
$336.06
Plus shipping costs $50.00
Shipping to: United States
Delivery in 7 to 10 Business Days

Quick Overview for Recombinant MUC16 (Sofituzumab Biosimilar) antibody (ABIN7488033)

Target

MUC16 (Sofituzumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
  • 1
Mammalian Cells

Clonality

  • 1
  • 1
Monoclonal

Conjugate

  • 2
This MUC16 (Sofituzumab Biosimilar) antibody is un-conjugated

Application

  • 1
  • 1
  • 1
  • 1
  • 1
ELISA

Grade

Research Grade
  • Expression System

    Mammalian cells

    Purpose

    Sofituzumab Biosimilar - Anti-MUC16, CA125 mAb

    Characteristics

    Antibody Type: IgG1-kappa

    Purification

    Recombinant antibody expressed in mammalien cells and purified.

    Isotype

    IgG1 kappa
  • Restrictions

    For Research Use only
  • Buffer

    PBS pH 7.5

    Storage

    -80 °C

    Storage Comment

    store at -80°C
  • Target

    MUC16 (Sofituzumab Biosimilar)

    Target Type

    Biosimilar

    Background

    DMUC5754A (conjugate),MMUC1206A (nonconjugate)
    Sofituzumab is investigated for the treatment of Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. Sofituzumab Vedotin (also known as DMUC5754A and RG-7458) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody (mAb) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl. DMUC5754A binds to the MUC16 extracellular domain with high affinity, and shows potent and selective anti-tumor activity in MUC16-expressing human ovarian cancer (OC) and pancreatic cancer (PC) mouse xenograft models. The targeted therapeutic strategy of DMUC5754A resulted in enhanced tumor-specific activity of MMAE, while minimizing exposure to tissues that do not express MUC16.

    CAS-No

    1418200-58-4
You are here:
Chat with us!